Pharma News, 2018

It’s not the worst flu season in the past decade, the Centers for Disease Control and Prevention shared during a press conference Friday morning.

Canada’s medicines regulator has issued a safety warning related to Boehringer Ingelheim’s idiopathic pulmonary fibrosis (IPF) therapy Ofev (nintedanib).

AstraZeneca’s biologic Fasenra has been approved for use in Europe as an add-on maintenance treatment in patients with severe eosinophilic asthma.

     SILVER SPRING, Md.

What happenedShares of Teva Pharmaceutical Industries (NYSE.

GlaxoSmithKline Plc’s new chief executive officer, Emma Walmsley, has revamped the top ranks of the U.

SAN FRANCISCO—David Hung is the CEO who sold his company, Medivation, to Pfizer for $14 billion.

The US Food and Drug Administration (FDA) has granted a breakthrough therapy designation to Shire’s investigational treatment for cytomegalovirus (CMV) infection in transplant patien...

Before patients can take prescriptions to a pharmacy and get their medications, FDA has to approve drugs first.

Sanofi and Regeneron are boosting their investment in development programmes for the PD-1 antibody cemiplimab in oncology and dupilumab in Type 2 (tissue specific) allergic diseases.

Arvinas and Pfizer have signed a research collaboration and license agreement relating to the discovery and development of protein degradation drug candidates.

Shire announced on Monday it would drop its revenue target of $20 billion by 2020, citing increased competition from generics and rival drug companies.